FDA Approves Guardant Health's Shield™ Colorectal Cancer Blood Test on Monday

Jul 29, 2024, 11:00 AM

The U.S. Food and Drug Administration (FDA) has approved Guardant Health's Shield™ blood test as a primary screening option for colorectal cancer. This approval on Monday not only facilitates Medicare reimbursement but also marks a significant advancement in colorectal cancer screening. Guardant Health's blood-based cancer test aims to detect cancer that begins in the colon or rectum, providing a non-invasive alternative to traditional screening methods.